UCB SA (EBR:UCB)
290.90
+0.70 (0.24%)
Nov 6, 2026, 5:35 PM CET
UCB SA Revenue
UCB SA had revenue of 4.27B EUR in the half year ending June 30, 2026, with 52.99% growth. This brings the company's total for the last twelve months to 8.52B, up 24.47% year-over-year. In the year 2025, UCB SA had annual revenue of 7.74B with 25.83% growth. That makes UCB SA the 1,545th largest company in the world by revenue and 6th in Belgium.
Revenue (ttm)
8.52B
Revenue Growth
+24.47%
P/S Ratio
6.51
Revenue / Employee
947.11K
Employees
9,000
Market Cap
55.46B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full UCB SA breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.74B | 1.59B | 25.83% |
| Dec 31, 2024 | 6.15B | 900.00M | 17.14% |
| Dec 31, 2023 | 5.25B | -265.00M | -4.80% |
| Dec 31, 2022 | 5.52B | -260.00M | -4.50% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
| Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
| Dec 31, 2018 | 4.63B | 102.00M | 2.25% |
| Dec 31, 2017 | 4.53B | 383.00M | 9.24% |
| Dec 31, 2016 | 4.15B | 271.00M | 6.99% |
| Dec 31, 2015 | 3.88B | 532.00M | 15.91% |
| Dec 31, 2014 | 3.34B | 211.00M | 6.73% |
| Dec 31, 2013 | 3.13B | -329.00M | -9.50% |
| Dec 31, 2012 | 3.46B | 216.00M | 6.65% |
| Dec 31, 2011 | 3.25B | 28.00M | 0.87% |
| Dec 31, 2010 | 3.22B | 102.00M | 3.27% |
| Dec 31, 2009 | 3.12B | -485.00M | -13.47% |
| Dec 31, 2008 | 3.60B | -25.00M | -0.69% |
| Dec 31, 2007 | 3.63B | 1.08B | 42.14% |
| Dec 31, 2006 | 2.55B | 210.00M | 8.97% |
| Dec 31, 2005 | 2.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| argenx SE | 5.21B |
| European Medical Solutions | 51.36M |
| Hyloris Pharmaceuticals | 9.83M |
| Onward Medical | 8.42M |
| Oxurion NV | 1.15M |
| Financière de Tubize | 13.26K |
| Celyad Oncology | 7.00K |
| BioSenic | -2.59M |
UCB SA News
- 4 days ago - UCB Partners With Cradle Therapeutics To Use AI In Antibody Drug Discovery - Nasdaq
- 17 days ago - Best Income Stocks to Buy for October 22nd - Nasdaq
- 18 days ago - United Community Banks (UCB) Q3 2026 Earnings Call Transcript - The Motley Fool
- 19 days ago - United Community Banks (UCB) Q3 Earnings Match Estimates - Nasdaq
- 23 days ago - FDA Approves New Self-Injection Option For UCB's ZILBRYSQ In Generalized Myasthenia Gravis - Nasdaq
- 23 days ago - United Community Banks (UCB) Q3 2026 Preview: EPS Est. $0.77, Reports October 20 - AlphaStreet
- 4 weeks ago - UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia - PRNewsWire
- 5 weeks ago - UCB SA Transcript: Investor update - Transcripts